Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Status:
NOT_YET_RECRUITING
Trial end date:
2032-02-15
Target enrollment:
Participant gender:
Summary
A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)